Osteogenesis Imperfecta Type V - Osteogenesis Imperfecta - page 177

[3] Strach EH. Hyperplastic callus formation in osteogenesis imper-
fecta; report of a case and review of the literature. J Bone Joint
Surg Br 1953;35-B(3):417-22.
[4] McCall RE, Bax JA. Hyperplastic callus formation in osteogen-
esis imperfecta following intramedullary rodding. J Pediatr
Orthop 1984;4(3):361-4.
[5] Kozlowski K, Bittner K. Unclassiied demineralising bone dis-
ease in an 8 years old girl (report of a case). Australas Radiol 1981;
25(1):76-80.
[6] Stoss H, Pontz B, Vetter U, Karbowski A, Brenner R, Spranger J.
Osteogenesis imperfecta and hyperplastic callus formation:
light- and electron-microscopic indings. Am J Med Genet 1993;
45(2):260.
[7] Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteo-
genesis imperfecta. J Med Genet 1979;16(2):101-16.
[8] Nakamura K, Kurokawa T, Nagano A, Umeyama T. Familial
occurrence of hyperplastic callus in osteogenesis imperfecta.
Arch Orthop Trauma Surg 1997;116(8):500-3.
[9] Kozlowski K. Osteogenesis imperfecta type V, spot diagnosis.
Pol J Radiol 2010;75(1):84-7.
[10] Moffatt P, Gaumond MH, Salois P, et al. Bril: a novel bone-speciic
modulator of mineralization. J Bone Miner Res 2008;23(9):1497-508.
[11] Cho TJ, Lee KE, Lee SK, et al. A single recurrent mutation in the
5′-UTR of IFITM5 causes osteogenesis imperfecta type V. Am J
Hum Genet 2012;91(2):343-8.
[12] Semler O, Garbes L, Keupp K, et al. A Mutation in the 5′-UTR of
IFITM5 creates an in-frame start codon and causes autosomal-
dominant osteogenesis imperfecta type V with hyperplastic cal-
lus. Am J Hum Genet 2012;91(2):349-57.
[13] Rauch F, Moffatt P, Cheung M, et al. Osteogenesis imperfecta
type V: marked phenotypic variability despite the presence
of the IFITM5 c.-14C>T mutation in all patients. J Med Genet.
2013;50(1):21-4.

FKBP11-CD81-FPRP complex and stimulates expression of
interferon-induced genes. Biochem Biophys Res Commun
2011;409(3):378-84.
[25] Hanagata N, Li X, Morita H, Takemura T, Li J, Minowa T.
Characterization of the osteoblast-speciic transmembrane pro-
tein IFITM5 and analysis of IFITM5-deicient mice. J Bone Miner
Metab 2011;29(3):279-90.
[26] Lange UC, Adams DJ, Lee C, et al. Normal germ line establish-
ment in mice carrying a deletion of the Iitm/Fragilis gene fam-
ily cluster. Mol Cell Biol 2008;28(15):4688-96.
[27] Zeitlin L, Rauch F, Travers R, Munns C, Glorieux FH. The effect
of cyclical intravenous pamidronate in children and adolescents
with osteogenesis imperfecta type V. Bone 2006;38(1):13-20.
[28] Semler O, Cheung MS, Glorieux FH, Rauch F. Wormian bones
in osteogenesis imperfecta: correlation to clinical indings and
genotype. Am J Med Genet A 2010;152A(7):1681-7.
[29] Kim OH, Jin DK, Kosaki K, et al. Osteogenesis imperfecta type V:
clinical and radiographic manifestations in mutation confirmed
patients. Am J Med Genet A. In press.

[30] Lee DY, Cho TJ, Choi IH, et al. Clinical and radiological mani-

festations of osteogenesis imperfecta type V. J Korean Med Sci
2006;21(4):709-14.

[31] Ramirez N, Vilella FE, Colon M, Flynn JM. Osteogenesis imperfecta

and hyperplastic callus formation in a family: a report of three cases
and a review of the literature. J Pediatr Orthop B 2003;12(2):88-96.

[32] Fassier AM, Rauch F, Aarabi M, Janelle C, Fassier F. Radial head

dislocation and subluxation in osteogenesis imperfecta. J Bone
Joint Surg Am 2007;89(12):2694-704.

[33] Cheung MS, Glorieux FH, Rauch F. Natural history of hyper-

plastic callus formation in osteogenesis imperfecta type V.
J Bone Miner Res 2007;22(8):1181-6.

[34] Battle WH, Shattock SG. A remarkable case of diffuse cancel-

lous osteoma of the femur, following a fracture, in which similar
growths afterwards developed in connection with other bones.
Proc R Soc Med 1908;1:83-115. (Pathol Sect).

[14] Moffatt P, Salois P, Gaumond MH, St-Amant N, Godin E,

Lanctot C. Engineered viruses to select genes encoding secreted
and membrane-bound proteins in mammalian cells. Nucleic
Acids Res 2002;30(19):4285-94.

[35] Dobrocky I, Seidl G, Grill F. MRI and CT features of hyperplastic

callus in osteogenesis imperfecta tarda. Eur Radiol 1999;9(4):665-8.

[15] Sallman Almen M, Bringeland N, Fredriksson R, Schioth HB.

The dispanins: a novel gene family of ancient origin that con-
tains 14 human members. PLoS One 2012;7(2):e31961.

[36] Vieira RL, Amaral DT, Jesus-Garcia FR, Saraiva G, Fernandes

AR, Resnick D. Hyperplastic callus formation in osteogenesis
imperfecta type V mimicking osteosarcoma: 4-year follow-up
with resolution. Skeletal Radiol 2006;35(6):402-5. [16] Hickford D, Frankenberg S, Shaw G, Renfree MB. Evolution of

vertebrate interferon inducible transmembrane proteins. BMC
Genomics 2012;13:155.

[37] Fujino T, Morii T, Tajima T, et al. Sporadic osteogenesis imper-

fecta type V in an 11-year-old Japanese girl. J Orthop Sci 2010;
15(4):589-93. [17] Brass AL, Huang IC, Benita Y, et al. The IFITM proteins mediate

cellular resistance to inluenza A H1N1 virus, West Nile virus,
and dengue virus. Cell 2009;139(7):1243-54.

[38] Cheung MS, Azouz EM, Glorieux FH, Rauch F. Hyperplastic cal-

lus formation in osteogenesis imperfecta type V: follow-up of
three generations over ten years. Skeletal Radiol 2008;37(5):465-7. [18] Yount JS, Moltedo B, Yang YY, et al. Palmitoylome proiling

reveals S-palmitoylation-dependent antiviral activity of IFITM3.
Nat Chem Biol 2012;6(8):610-4.

[39] Rieker O, Kreitner KF, Karbowski A. Hyperplastic callus for-

mation in osteogenesis imperfecta: CT and MRI indings. Eur
Radiol 1998;8(7):1137-9. [19] Yount JS, Karssemeijer RA, Hang HC. S-palmitoylation and

ubiquitination differentially regulate interferon-induced trans-
membrane protein 3 (IFITM3)-mediated resistance to inluenza
virus. J Biol Chem 2012;287(23):19631-19641.

[40] Land C, Rauch F, Glorieux FH. Cyclical intravenous pami-

dronate treatment affects metaphyseal modeling in grow-
ing patients with osteogenesis imperfecta. J Bone Miner Res
2006;21(3):374-9. [20] Jia R, Pan Q, Ding S, et al. The N-terminal region of IFITM3

modulates its antiviral activity through regulating IFITM3 cel-
lular localization. J Virol 2012;86(24):13697-13707.

[41] Cho TJ, Choi IH, Chung CY, Yoo WJ, Park MS, Park YK. Eficacy

of oral alendronate in children with osteogenesis imperfecta.
J Pediatr Orthop 2005;25(5):607-12. [21] Bailey CC, Huang IC, Kam C, Farzan M. Iitm3 limits the sever-

ity of acute inluenza in mice. PLoS Pathog 2012;8(9):e1002909. [42] Arundel P, Ofiah A, Bishop NJ. Evolution of the radiographic

appearance of the metaphyses over the irst year of life in type V
osteogenesis imperfecta: clues to pathogenesis. J Bone Miner Res
2011;26(4):894-8.

[22] Liu Y, Liu H, Titus L, Boden SD. Natural antisense transcripts

enhance bone formation by increasing sense IFITM5 transcrip-
tion. Bone 2012;51(5):933-8.

[23] Hanagata N, Takemura T, Monkawa A, Ikoma T, Tanaka J.

Phenotype and gene expression pattern of osteoblast-like cells
cultured on polystyrene and hydroxyapatite with pre-adsorbed
type-I collagen. J Biomed Mater Res A 2007;83(2):362-71.

[43] Fleming F, Woodhead HJ, Briody JN, et al. Cyclic bisphospho-

nate therapy in osteogenesis imperfecta type V. J Paediatr Child
Health 2005;41(3):147-51.

[44] Kasaai B, Gaumond MH, Moffatt P. Regulation of the bone-

restricted IFITM-like (Bril) gene transcription by Sp and Gli family
members and CpG methylation. J Biol Chem 2013;288(19):13278-94.

[24] Hanagata N, Li X. Osteoblast-enriched membrane pro-

tein IFITM5 regulates the association of CD9 with an